14th Alzheimer’s & Parkinson’s Drug Development Summit 2026

 

Capitalizing on the surge of innovation across new targets, lessons learned from clinical setbacks, groundbreaking progress in blood-based diagnostics, and more, the 14th Alzheimer’s & Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical and regulatory.

In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting the latest trailblazing innovation, from novel interventions for disease modification, encompassing protein aggregation, neuroinflammation, metabolic pathways, neurotrophic factors and more to the groundbreaking progress in p-tau217 and fluid-based biomarkers.

The 2026 program is built to explore disease progression, modification and prodromal intervention, so the next generation of therapeutics can prevent as well provide a meaningful impact to neurodegenerative patients in need.

More Info

---

---